Foghorn Therapeutics (NASDAQ:FHTX – Get Rating) had its price objective reduced by Wedbush from $25.00 to $20.00 in a research note issued to investors on Friday morning, Benzinga reports. They currently have an outperform rating on the stock. Wedbush also issued estimates for Foghorn Therapeutics’ Q1 2024 earnings at ($0.41) EPS, Q2 2024 earnings at ($0.42) EPS, Q3 2024 earnings at ($0.46) EPS, Q4 2024 earnings at ($0.49) EPS and FY2027 earnings at $4.14 EPS.
A number of other equities research analysts have also recently commented on FHTX. Morgan Stanley lowered their price objective on shares of Foghorn Therapeutics from $15.00 to $14.00 and set an equal weight rating on the stock in a research note on Monday, November 21st. HC Wainwright reaffirmed a buy rating and issued a $25.00 price objective on shares of Foghorn Therapeutics in a research report on Friday. Finally, BMO Capital Markets started coverage on Foghorn Therapeutics in a research report on Thursday, January 5th. They issued an outperform rating and a $20.00 price objective for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of $20.00.
Foghorn Therapeutics Stock Performance
FHTX stock opened at $5.21 on Friday. Foghorn Therapeutics has a one year low of $4.51 and a one year high of $18.12. The company has a fifty day moving average of $6.96 and a 200-day moving average of $7.66. The stock has a market capitalization of $217.78 million, a PE ratio of -1.99 and a beta of 2.15.
Institutional Investors Weigh In On Foghorn Therapeutics
Foghorn Therapeutics Company Profile
Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
- Get a free copy of the StockNews.com research report on Foghorn Therapeutics (FHTX)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for Foghorn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foghorn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.